Table 3 Post-lung transplant outcomes
Allo-HSCT cohort (n = 19) | Matched controls (n = 38) | p value | |
|---|---|---|---|
ICU length of stay (LOS), days | |||
Median [IQR] | 4.0 [2.0–25.5] | 3.3 [2.0–5.3] | 0.298 |
Post-LTx hospital LOS, days | |||
Median [IQR] | 23.1 (17.0–101.0) | 17.0 [13.8–26.0] | 0.009 |
Biopsy proven acute cellular rejection1 | |||
Any ACR grade | 47.3% (9) | 65.8% (25) | 0.253 |
ACR > A1B0 | 21.1% (4) | 34.2% (13) | 0.370 |
ACR treatment in the 1st post-LTx year | 31.6% (6) | 52.6% (20) | 0.165 |
Antibody mediated rejection | |||
Presence of dnDSA2 | 20% (4 of 15) | 59% (22 of 37) | 0.041 |
Time to DSA | 73.5 days | 87.0 days | 0.777 |
Treatment for AMR | 0% | 21.1% (8) | 0.042 |
CMV viraemia | |||
CMV D + /R- match | 100% (3) | 75% (6) | > 0.99 |
CMV D-/R + or D + /R + match | 30% (3) | 27.8% (5) | |
BAL microbiology3 | |||
Category 1 pathogens | 63.2% (12) | 76.3% (29) | 0.356 |
Category 2 pathogens | 57.9% (11) | 36.8% (14) | 0.163 |
Category 1 or 2 | 79.0% (15) | 76.3% (29) | > 0.99 |
Severe infections4 | |||
Percentage of patients | 68.4% (13) | 55.3% (21) | 0.401 |
Incidence of severe infections | 0.67 severe infections per patient per year | 0.36 severe infections per patient per year | 0.0705 |
Chronic rejection | |||
CLAD-free at 3 years | 78.0% | 74.9% | 0.721 |
Median time to CLAD | 4.98 years | Undefined | 0.622 |
Graft survival | |||
1-year survival | 100% | 97.1% | 0.473 |
5-year survival | 50.0% | 68.5% | 0.161 |
10-year survival | 25.0% | 56.1% | 0.059 |
CLAD-free survival | |||
3-year CLAD free survival | 52.1% | 71.1% | 0.306 |
Median CLAD free survival | 4.26 years | Undefined | 0.142 |
Re-Transplant | 0% | 7.9% (3) | 0.544 |